CUBIST PHARMACEUTICALS

Health Issues

Healthcare Reform Implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens including breakpoints; antibiotic resistance among elderly population; issues related to 340B Drug Pricing Program; reimbursement issues for antibiotics Issues concerning incenting antibiotic development. H.R. 3204, The Drug Quality and Security Act and S. 959, The Pharmaceutical Quality, Security and Accountability Act as they relate to the tracking and tracing of pharmaceutical drugs; issues related to antibiotics and breakpoints. Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152) Implementation of the American Taxpayer Relief Act of 2012 Pub.L 112-240, H.R. 8 Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L.112-144) S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013 S. 959, Pharmaceutical Compounding Quality and Accountability Act H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act.

TargetedSENATE · HOUSE OF REPRESENTATIVES

Medicare/Medicaid

Issues related to Medicare reimbursement for new technologies in the following; S. Con. Res. 8 - Concurrent Resolution on the Budget for FY 2014 H. Con. Res. 25 - Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033 H. J. Res. 59 - Continuing Appropriations Resolution, 2014